AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Average Target Price from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $54.64.

Several research firms recently commented on ANAB. HC Wainwright cut their price objective on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. UBS Group lifted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wedbush restated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a report on Thursday, November 14th. Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Finally, Guggenheim lifted their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st.

Insider Activity at AnaptysBio

In other news, insider Eric J. Loumeau sold 8,720 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the sale, the insider now directly owns 7,020 shares in the company, valued at approximately $279,536.40. This trade represents a 55.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The trade was a 8.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock worth $892,936 in the last quarter. 33.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio during the first quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in AnaptysBio during the first quarter worth about $265,000. Acadian Asset Management LLC acquired a new stake in AnaptysBio in the 1st quarter valued at about $420,000. Platinum Investment Management Ltd. acquired a new position in shares of AnaptysBio during the 1st quarter worth approximately $1,490,000. Finally, StemPoint Capital LP lifted its position in AnaptysBio by 499.0% during the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after buying an additional 224,548 shares in the last quarter.

AnaptysBio Stock Up 5.8 %

ANAB opened at $19.97 on Friday. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31. The stock’s 50 day moving average price is $30.73 and its two-hundred day moving average price is $29.89. The firm has a market capitalization of $607.69 million, a P/E ratio of -3.11 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. As a group, analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.